/*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} Q16E Question: (Accounting for R&... [FREE SOLUTION] | 91Ó°ÊÓ

91Ó°ÊÓ

Question: (Accounting for R&D Costs) Price Company from time to time embarks on a research program when a special project seems to offer possibilities. In 2016, the company expends \(325,000 on a research project, but by the end of 2016 it is impossible to determine whether any benefit will be derived from it.

Instructions

  1. What account should be charged for the \)325,000, and how should it be shown in the financial statements?
  2. The project is completed in 2017, and a successful patent is obtained. The R&D costs to complete the project are \(110,000. The administrative and legal expenses incurred in obtaining patent number 472-1001-84 in 2017 total \)16,000. The patent has an expected useful life of 5 years. Record these costs in journal entry form. Also, record patent amortization (full year) in 2017.
  3. In 2018, the company successfully defends the patent in extended litigation at a cost of \(47,200, thereby extending the patent life to December 31, 2025. What is the proper way to account for this cost? Also, record patent amortization (full year) in 2018.
  4. Additional engineering and consulting costs incurred in 2018 required to advance the design of a product to the manufacturing stage total \)60,000. These costs enhance the design of the product considerably. Discuss the proper accounting treatment for this cost.

Short Answer

Expert verified

Answer

  1. Total cost should be disclosed in the notes of the financial statements
  2. Amortization expense =$3,200
  3. Totalone year’s amortization expense = $7,500
  4. Additional engineering and consulting costs required

Step by step solution

01

Meaning of Intangible Asset

Intangible assets are identified as non-monetary assets that have no physical existence, according to the International Financial Reporting Standards (IFRS). Intangible assets, like other assets, are intended to create future financial returns for the organization.

02

Explaining the amount that should be charged for the $325,000 and its reporting in financial statements

According to GAAP, the $325,000 is a research and development expenditure that should be charged to the R&D Expense, and the overall cost of R&D should be separately declared in the notes to the financial statements if not separately stated in the income statement.

03

 Step 3: Preparing journal entries (b)

Date

Particular

Debit ($)

Credit ($)

Research and Development Expense

110,000

Cash, Accts. Payable, etc.

110,000

(To record research and development costs)

Patents

16,000

Cash, Accts. Payable, etc.

16,000

(To record legal and administrative costs incurred to obtain a patent)

Amortization Expense

3,200

Patents

3,200

(To record one year’s amortization expense)

Working Notes:

Calculating the amount of amortization expense

Amortizationexpense=PatentcostUsefullife=$16,0005=$3,200

04

Preparing journal entries (c)

Date

Particular

Debit ($)

Credit ($)

Patents

47,200

Cash, Accts. Payable, etc.

47,200

(To record legal cost of successfully defending patent)

Since the defense was successful and the patent's useful life was prolonged, the expense of defending the patent is capitalized.

Date

Particular

Debit ($)

Credit ($)

Amortization Expense

7,500

Patents

7,500

(To record one year’s amortization Expense)

WorkingNotes:Calculationofone-yearamortizationexpenseInitialAmortizationexpense=Patents-AmortizationexpenseUsefullife=$16,000-$3,2008=$12,0008=$1,600Totalamortizationexpense=Initialamortization+Endingamortization=$1,600+$5,900=$7,500

05

Explaining the proper accounting treatment for the cost (d)

R & D costs are the additional engineering and consulting expenditures necessary to progress a product's concept to the production stage. It is R&D since it turns information into a strategy or design for a new product, as stated in the chapter.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

Merck and Johnson & Johnson

Question: Merck & Co., Inc. and Johnson & Johnson are two leading producers of healthcare products. Each has considerable assets, and each expends considerable funds each year toward the development of new products. The development of a new healthcare product is often very expensive, and risky. New products frequently must undergo considerable testing before approval for distribution to the public. For example, it took Johnson & Johnson 4 years and \(200 million to develop its 1-DAY ACUVUE contact lenses. Below are some basic data compiled from the financial statements of these two companies.

(all dollars in millions)

Johnson & Johnson

Merck

Total assets

\)53,317

\(42,573

Total revenue

47,348

22,939

Net income

8,509

5,813

Research and development expense

5,203

4,010

Intangible assets

11,842

2,765

Instructions

  1. What kinds of intangible assets might a healthcare products company have? Does the composition of these intangibles matter to investors—that is, would it be perceived differently if all of Merck’s intangibles were goodwill than if all of its intangibles were patents?
  2. Suppose the president of Merck has come to you for advice. He has noted that by eliminating research and development expenditures the company could have reported \)4 billion more in net income. He is frustrated because much of the research never results in a product, or the products take years to develop. He says shareholders are eager for higher returns, so he is considering eliminating research and development expenditures for at least a couple of years. What would you advise?
  3. The notes to Merck’s financial statements note that Merck has goodwill of $1.1 billion. Where does recorded goodwill come from? Is it necessarily a good thing to have a lot of goodwill on a company’s books?

On July 1, 2017, Wheeler Company purchased \(4,000,000 of Duggan Company’s 8% bonds, due on July 1, 2024. The bonds, which pay interest semiannually on January 1 and July 1, were purchased for \)3,500,000 to yield 10%. Determine the amount of interest revenue Wheeler should report on its income statement for the

year ended December 31, 2017.

Gershwin Corporation obtained a franchise from Sonic Hedgehog Inc. for a cash payment of $120,000 on April 1, 2017. The franchise grants Gershwin the right to sell certain products and services for a period of 8 years. Prepare Gershwin’s April 1 journal entry and December 31 adjusting entry.

Research and development activities may include (a) personnel costs, (b) materials and equipment costs, and (c) indirect costs. What is the recommended accounting treatment for these three types of R&D costs?

Use the information from BE17-5 but assume the stock is nonmarketable. Prepare Fairbanks’ journal entries to record (a) the purchase of the investment, (b) the dividends received, and (c) the fair value adjustment, if any.

See all solutions

Recommended explanations on Business Studies Textbooks

View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.